Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study) | Zendy

Stefano Bonora | Zendy; Stefano Rusconi | Zendy; Andrea Calcagno | Zendy; Margherita Bracchi | Zendy; Ottavia Viganò | Zendy; Jessica Cusato | Zendy; Massimiliano Lanzafame | Zendy; Alice Trentalange | Zendy; Letizia Marinaro | Zendy; Marco Siccardi | Zendy; Antonio D’Avolio | Zendy; Massimo Galli | Zendy; Giovanni Di Perri | Zendy

Open Access

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)

Author(s) -

Stefano Bonora,

Stefano Rusconi,

Andrea Calcagno,

Margherita Bracchi,

Ottavia Viganò,

Jessica Cusato,

Massimiliano Lanzafame,

Alice Trentalange,

Letizia Marinaro,

Marco Siccardi,

Antonio D’Avolio,

Massimo Galli,

Giovanni Di Perri

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv208

Subject(s) - atazanavir , ritonavir , medicine , tolerability , bioequivalence , pharmacogenetics , pharmacology , pharmacokinetics , human immunodeficiency virus (hiv) , genotype , viral load , adverse effect , antiretroviral therapy , virology , biology , gene , biochemistry

Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research